Skip to content

Biohaven BHVN AFS Securities

AFS Securities at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$0
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$894.72M+186%
Biogen logo
BiogenBIIB
$454.7M-32.0%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%
Enterprise value$2.26B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's AFS securities?
Biohaven (BHVN) reported AFS securities of $150.53M in Q1 2026.
How has Biohaven's AFS securities changed year-over-year?
Biohaven's AFS securities decreased by 32.9% year-over-year, from $224.29M to $150.53M.
What is the long-term trend for Biohaven's AFS securities?
Over 3 years (2022 to 2025), Biohaven's AFS securities has grown at a -28.4% compound annual growth rate (CAGR), from $310.51M to $114.11M.
What does AFS securities mean?
Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.